Tag Archives: biosimilars arthritis

Juvenile Arthritis Advocates

Young Advocates in Pennsylvania Speak Out

School is out, so now what do you do to engage your kids? On June 29, a number of parents took their families to Harrisburg, PA, to participate in the 2016 Pennsylvania Advocacy and Access Day. Some of the youth were already pros having attended previous advocacy days and our Advocacy Summit in Washington, DC. For others it was a first time experience.
Continue reading Young Advocates in Pennsylvania Speak Out

Arthritis Foundation State Advocacy

Arthritis Foundation Collaborates with Providers at the State Level to Advocate for the Arthritis Community

Our advocacy team is incredibly active at the state level, leading the way to make sure that arthritis patients have access to critical medications. Our volunteer Advocates make a significant impact and help achieve tangible results by sharing their stories and asking elected officials to support legislation that is important to them and their families. But beyond fighting for key legislative changes and being vocal in raising awareness and sharing stories that help put faces with arthritis, we also make strides for the arthritis community when we link the voices of patient with the provider community – as we have done recently and successfully in New York and Ohio.
Continue reading Arthritis Foundation Collaborates with Providers at the State Level to Advocate for the Arthritis Community

Arizona Advocacy Biosimilars Arthritis

Arizona Arthritis Advocates Achieve Biosimilar Substitution Victory!

With new, innovative arthritis medications coming to market, patients with arthritis may soon have access to potentially less expensive biosimilar medications (similar to biologics).

However, imagine that, without your knowledge, your pharmacy substituted the biologic medication prescribed by your doctor with a new interchangeable biosimilar. Residents of Arizona no longer have to worry because this week, Arizona Governor Doug Ducey signed House Bill 2310 (HB 2310) into law. HB 2310 allows pharmacists to substitute biologic medications with new, interchangeable and potentially less expensive biosimilar medications when they come to market. The bill also ensures patients and their physicians know when a substitution occurs, resulting in a complete and accurate patient medical record. And, if physicians do not want a substitution to occur, they can stipulate that the prescription be dispensed as written.
Continue reading Arizona Arthritis Advocates Achieve Biosimilar Substitution Victory!

Advocacy Kentucky Biosimilars Step Therapy

Advocates in Kentucky Get a Big Win for Biosimilar Substitution

Big news for our arthritis community in Kentucky! On April 13, 2016, Gov. Matt Bevin (R – KY) signed Senate Bill 134 into law. The law creates a pathway for the introduction and use of biosimilars into the mainstream marketplace. Biosimilar medications have the potential to provide safe and effective treatment to people with arthritis at a potentially lower cost than name-brand biologic medications.

The many letters, calls and visits made by Arthritis Foundation Advocates in Kentucky played a significant role in the passage of SB 134.
Continue reading Advocates in Kentucky Get a Big Win for Biosimilar Substitution